UY30060A1 - Inhibición de la rho quinasa mediada por arni para el tratamiento de trastornos - Google Patents

Inhibición de la rho quinasa mediada por arni para el tratamiento de trastornos

Info

Publication number
UY30060A1
UY30060A1 UY30060A UY30060A UY30060A1 UY 30060 A1 UY30060 A1 UY 30060A1 UY 30060 A UY30060 A UY 30060A UY 30060 A UY30060 A UY 30060A UY 30060 A1 UY30060 A1 UY 30060A1
Authority
UY
Uruguay
Prior art keywords
treatment
rho kinase
disorders
arni
inhibition
Prior art date
Application number
UY30060A
Other languages
English (en)
Inventor
Jon E Chatterton
Abbor F Clark
Original Assignee
Alcon Mfg Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Mfg Ltd filed Critical Alcon Mfg Ltd
Publication of UY30060A1 publication Critical patent/UY30060A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se presenta la interferencia del ARN para inhibir la expresión del ARNm de la Rho Quinasa para el tratamiento de pacientes con trastornos oculares, en particular para el tratamiento de la presión intraocular, la hipertensión ocular y el glaucoma. Los objetivos del ARNm de la Rho quinasa incluyen el ARNm para ROCK1 y ROCK2.
UY30060A 2005-12-27 2006-12-21 Inhibición de la rho quinasa mediada por arni para el tratamiento de trastornos UY30060A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75409405P 2005-12-27 2005-12-27

Publications (1)

Publication Number Publication Date
UY30060A1 true UY30060A1 (es) 2007-04-30

Family

ID=38218805

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30060A UY30060A1 (es) 2005-12-27 2006-12-21 Inhibición de la rho quinasa mediada por arni para el tratamiento de trastornos

Country Status (14)

Country Link
US (4) US20070149473A1 (es)
EP (2) EP1989305A2 (es)
JP (2) JP2009532325A (es)
KR (1) KR20080079264A (es)
CN (1) CN101326285A (es)
AR (1) AR057252A1 (es)
AU (1) AU2006330606A1 (es)
BR (1) BRPI0621264A2 (es)
CA (2) CA2821393A1 (es)
RU (2) RU2432165C2 (es)
TW (1) TW200731979A (es)
UY (1) UY30060A1 (es)
WO (1) WO2007076367A2 (es)
ZA (1) ZA200805599B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1910297B1 (en) * 2005-07-11 2016-05-25 Aerie Pharmaceuticals, Inc. Isoquinoline compounds
US20070135499A1 (en) * 2005-07-11 2007-06-14 Aerie Pharmaceuticals, Inc. Hydrazide compounds
WO2008036540A2 (en) 2006-09-20 2008-03-27 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US8455513B2 (en) * 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
EP2192926A1 (en) * 2007-10-01 2010-06-09 Alcon Research, Ltd. Self complementary aav-mediated delivery of interfering rna molecules to treat or prevent ocular disorders
US7973019B1 (en) 2007-10-03 2011-07-05 Alcon Research, Ltd. Transferrin/transferrin receptor-mediated siRNA delivery
TW200930405A (en) 2007-11-15 2009-07-16 Alcon Res Ltd Low density lipoprotein receptor-mediated siRNA delivery
AR069704A1 (es) 2007-12-18 2010-02-10 Alcon Res Ltd Sistema de administracion de rnai de interferencia y usos del mismo
US8455514B2 (en) 2008-01-17 2013-06-04 Aerie Pharmaceuticals, Inc. 6-and 7-amino isoquinoline compounds and methods for making and using the same
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
CN101643729B (zh) * 2008-08-07 2011-12-28 复旦大学 核酸分子nrn1sr22及其在制备抗癌药物中的应用
US8394826B2 (en) 2009-05-01 2013-03-12 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
WO2011021221A2 (en) 2009-08-17 2011-02-24 Reliance Life Sciences Pvt. Ltd. Compositions for spinal cord injury
ES2730393T3 (es) * 2010-10-28 2019-11-11 Benitec Biopharma Ltd Tratamiento contra el VHB
CN102343091A (zh) * 2011-03-01 2012-02-08 中国科学技术大学 一种基于ezrin磷酸化的物质及其应用
WO2012161677A1 (en) 2011-05-20 2012-11-29 Alcon Research, Ltd. TRANSFERRIN/TRANSFERRIN RECEPTOR-MEDIATED siRNA DELIVERY
WO2013103467A1 (en) 2012-01-06 2013-07-11 Alcon Research, Ltd. Interfering rna delivery system and uses thereof
EP3811943B1 (en) 2013-03-15 2023-02-22 Aerie Pharmaceuticals, Inc. Compound for use in the treatment of ocular disorders
CA3005707C (en) 2015-11-17 2023-11-21 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
BR112019003945A2 (pt) 2016-08-31 2019-05-21 Aerie Pharmaceuticals, Inc. composições oftálmicas
CN111471653B (zh) * 2017-03-01 2022-11-25 中国科学院动物研究所 一种将非神经元细胞转化为神经元细胞的方法
CN110506037A (zh) 2017-03-31 2019-11-26 爱瑞制药公司 芳基环丙基-氨基-异喹啉酰胺化合物
WO2020056345A1 (en) 2018-09-14 2020-03-19 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
WO2023056295A1 (en) * 2021-09-30 2023-04-06 Regeneron Pharmaceuticals, Inc. Treatment of glaucoma with rho guanine nucleotide exchange factor 12 (arhgef12) inhibitors
WO2023239756A1 (en) 2022-06-07 2023-12-14 Generation Bio Co. Lipid nanoparticle compositions and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ308053B6 (cs) * 2000-12-01 2019-11-27 Max Planck Gesellschaft Izolovaná molekula dvouřetězcové RNA, způsob její výroby a její použití
US20050222029A1 (en) * 2001-01-04 2005-10-06 Myriad Genetics, Incorporated Compositions and methods for treating diseases
US20040115641A1 (en) * 2002-12-11 2004-06-17 Isis Pharmaceuticals Inc. Modulation of ROCK 1 expression
DK2284266T3 (da) * 2002-11-14 2014-01-13 Thermo Fisher Scient Biosciences Inc sIRNA-MOLEKYLE MOD TP53
US20050019746A1 (en) * 2003-01-23 2005-01-27 Eirx Therapeutics Limited Apoptosis-related kinase/GPCRs
US20070054848A1 (en) * 2003-03-28 2007-03-08 Masaya Tohyama Composition and method for nerve regeneration
NZ546088A (en) * 2003-08-27 2009-10-30 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders using a PDGF antagonist and a VEGF antagonist
AU2003300239A1 (en) * 2003-12-29 2005-07-21 Galapagos Genomics N.V. Modulators of bone homeostasis identified in a high-throughput screen
WO2005085469A2 (en) * 2004-03-09 2005-09-15 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with rho-associated protein kinase 1 (rock1)
WO2005085466A2 (en) * 2004-03-09 2005-09-15 Bayer Healtcare Ag Diagnostic and therapeutics for diseases associated with rho-associated protein kinase 2 (rock2)
WO2005117938A2 (en) * 2004-04-13 2005-12-15 Regents Of The University Of Minnesota Methods of treating ocular conditions

Also Published As

Publication number Publication date
WO2007076367A3 (en) 2008-04-17
BRPI0621264A2 (pt) 2011-12-06
CA2631840A1 (en) 2007-07-05
US8168609B2 (en) 2012-05-01
EP2592144A1 (en) 2013-05-15
ZA200805599B (en) 2009-11-25
KR20080079264A (ko) 2008-08-29
RU2432165C2 (ru) 2011-10-27
TW200731979A (en) 2007-09-01
CN101326285A (zh) 2008-12-17
US20070149473A1 (en) 2007-06-28
JP2012193210A (ja) 2012-10-11
RU2011124528A (ru) 2012-12-27
US20090275641A1 (en) 2009-11-05
AR057252A1 (es) 2007-11-21
WO2007076367A2 (en) 2007-07-05
US20110245319A1 (en) 2011-10-06
CA2821393A1 (en) 2007-07-05
AU2006330606A1 (en) 2007-07-05
JP2009532325A (ja) 2009-09-10
US20120178794A1 (en) 2012-07-12
RU2008130855A (ru) 2010-02-10
EP1989305A2 (en) 2008-11-12

Similar Documents

Publication Publication Date Title
UY30060A1 (es) Inhibición de la rho quinasa mediada por arni para el tratamiento de trastornos
CR20110077A (es) Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
UY29348A1 (es) Inhibición de objetivos oculares mediada por arni
UY38263A (es) Compuestos de purinona y su uso en el tratamiento del cáncer
ECSP10010510A (es) Compuestos del inhibidor de raf y métodos de uso de los mismos
CL2011003266A1 (es) Compuestos derivados de imidazolidin-2-ona, con actividad inhibidora de 17alfa-hidroxilasa/liasa-c17,20; composicion farmaceutica que los comprende; y uso en el tratamiento de inflamacion o cancer, entre otras.
CR11678A (es) Combinaciones de un conjugado anticuerpo-farmaco anti-her2 y agentes quimioterapeuticos y los metodos de uso
CR20110131A (es) Derivados de prostaglandinas
CL2008002294A1 (es) Compuestos derivados de benzotiazol acetamida y sus sales farmaceuticamente aceptables; composicion farmaceutica de dichos compuestos; su uso para tratar enfermedades mediadas por pi3 quinasa incluyendo melanoma, carcinoma y otras condiciones derivadas del cancer.
ECSP099414A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteína quinasa
CR20120289A (es) Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
UA111756C2 (uk) Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
CO6612188A2 (es) Derivados de prindina y pirazina como moduladores de cinasa de proteina
WO2008029276A3 (en) Compositions and methods for the treatment of ophthalmic disease
AR062402A1 (es) Uso de compuestos y derivados de 2,5-dihidroxibenceno para el tratamiento del cancer de piel
WO2014194245A3 (en) Cdk8 inhibitors and uses thereof
CL2008000089A1 (es) Compuestos derivados de 2,4-pirimidinona condensada con un heterociclo, inhibidores de pde-4; composicion farmaceutica; combinacion farmaceutica; procedimiento de preparacion de los compuestos, utiles para tratar trastornos inmunes e inflamatorios.
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
AR062401A1 (es) Uso de derivados del 2,5-dihidroxibenceno para tratar dermatitis
GT200600277A (es) Derivados de prostaglandina
WO2014194242A3 (en) Flt3 inhibitors and uses thereof
UY33153A (es) Formulación tópica oftálmica de péptidos
ES2421605T3 (es) Inhibidores de trastorno isquémico o enfermedades
ATE525349T1 (de) Pharmazeutische prostaglandinzusammensetzungen
CL2022000225A1 (es) Forma polimórfica estable de 6-fluoro-9-metil-9h-ß-carbolina y usos de la misma

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181003